Table 3 Multivariate analysis of prognostic factor for OS in each treatment group
Treatment groups | |||||||||
|---|---|---|---|---|---|---|---|---|---|
60 Gy in 30 fr | 60 Gy in 20 fr | 40 Gy in 15 fr | |||||||
HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | |
Age | |||||||||
(≥65 vs. <65) | 1.58 (0.94-2.65) | 0.085 | 2.05 (1.04-4.06) | 0.039 | 0.69 (0.18-2.60) | 0.58 | |||
KPS | |||||||||
(≥70 vs <70) | 1.52 (0.53-4.38) | 0.443 | 0.63 (0.27-1.47) | 0.285 | 0.27 (0.11-0.66) | 0.004 | |||
Extent of surgery | |||||||||
(STR vs. biopsy) | 0.47 (0.19-1.17) | 0.103 | 0.62 (0.30-1.25) | 0.179 | 1.29 (0.33-0.99) | 0.713 | |||
(GTR vs. biopsy) | 0.33 (0.12-0.90) | 0.031 | 0.29 (0.13-0.66) | 0.003 | 0.20 (0.04-1.15) | 0.071 | |||
Chemotherapy | |||||||||
(Yes vs. no) | 0.34 (0.10-1.12) | 0.075 | 0.11 (0.01-0.97) | 0.047 | 0.62 (0.24-1.62) | 0.330 | |||
Repeat surgery | |||||||||
(Yes vs. no) | 0.73 (0.48-1.12) | 0.149 | 0.35 (0.18-0.69) | 0.002 | 0.18 (0.02-1.89) | 0.154 | |||
MGMT | |||||||||
(Methylated vs. unmethylated) | 0.46 (0.29-0.72) | 0.001 | 0.37 (0.20-0.68) | 0.002 | 0.57 (0.18-1.78) | 0.329 | |||